[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332693-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332693-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-immune-related-27-gene-signature-determaio-predicts-response-to-neoadjuvant-atezolizumab-plus-chemotherapy-in-triple-negative-breast-cancer","The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer","","Assessed the 27-gene RT-qPCR–based DetermaIO assay and an RNA-seq–derived equivalent score as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 trial, comparing neoadjuvant carboplatin/nab-paclitaxel plus atezolizumab versus chemotherapy alone in stage II/III triple-negative breast cancer. Concordance between RNA-seq and RT-qPCR IO scores was high; DetermaIO-positive patients showed higher pCR with atezolizumab, while benefit in DetermaIO-negative cases was similar across arms. PDL1 protein and stromal TIL counts were non-predictive; conclusions were supported in I-SPY2.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-immune-related-27-gene-signature-determaio-predicts-response-to-neoadjuvant-atezolizumab-plus-chemotherapy-in-triple-negative-breast-cancer/332693/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-immune-related-27-gene-signature-determaio-predicts-response-to-neoadjuvant-atezolizumab-plus-chemotherapy-in-triple-negative-breast-cancer/332693.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does DetermaIO evaluate in triple-negative breast cancer?","Question",{"text":63,"@type":64},"DetermaIO is a 27-gene RT-qPCR–based assay that generates an immune-related score. The study evaluates whether this score predicts sensitivity to immune checkpoint therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were DetermaIO results validated in this research?",{"text":68,"@type":64},"The study compared the DetermaIO score from RT-qPCR with an equivalent score calculated from RNA-seq data. It further assessed predictive performance across trials, including neoTRIPaPDL1 and I-SPY2.",{"name":70,"@type":61,"acceptedAnswer":71},"Does PD-L1 expression predict benefit from atezolizumab in these analyses?",{"text":72,"@type":64},"No. The study reports that PDL1 protein expression was not predictive of differential benefit from atezolizumab.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332693,1790806211,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer  \nMatteo Dugo1, Chiun-Sheng Huang2, Daniel Egle3, Begoña Bermejo4, Claudio Zamagni5, Robert S. Seitz6, Tyler J. Nielsen6, Marc Thill7, Antonio Antn-Torres8, Stefania Russo9,  \nEva Maria Ciruelos10, Brock L. Schweitzer6, Douglas T. Ross6, Barbara Galbardi1, Richard Greil11, Vladimir Semiglazov12, Balzs Gyorffy13,14,15, Marco Colleoni16, Catherine M. Kelly17, Gabriella Mariani18, Lucia Del Mastro19, Olivia Blasi16, Maurizio Callari20, Lajos Pusztai21, Pinuccia Valagussa20,†, Giuseppe Viale16, Luca Gianni20, and Giampaolo Bianchini1,22  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: We assessed the 27-gene RT-qPCR–based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neoadjuvant carboplatin/nab-paclitaxel chemotherapy (CT) plus atezolizumab with CT alone in stage II/III triple-negative breast cancer. We also assessed the predictive function of the immunooncology (IO) score in expression data of patients treated with pembrolizumab plus paclitaxel (N ¼ 29) or CT alone (N ¼ 56) in the I-SPY2 trial.\u003Cbr>Experimental Design: RNA-seq data were obtained from pretreatment core biopsies from 242 (93.8%) of the 258 patients in the per-protocol-population. The DetermaIO RT-qPCR test, performed in the CAP/CLIA-accredited laboratory of Oncocyte Corp., was available for 220 patients (85.3%) . A previously established threshold was used to assign DetermaIO-positive\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | versus DetermaIO-negative status. Publicly available microarray data were used from I-SPY2 .\u003Cbr>Results: IO scores calculated from RNA-seq and RT-qPCR data were highly concordant. In neoTRIPaPDL1, DetermaIO-positive cancers (N ¼ 92, 41.8%) had pathologic complete response (pCR) rates of 69.8% and 46.9% in the CT + atezolizumab and CT arms, respectively. In DetermaIO-negative cases, pCR rates were similar in both arms (44.6% vs. 49.2%; interaction test P ¼ 0.04). PDL1 protein expression and stromal tumor–infiltrating lymphocyte count were not predictive of differential benefit from atezolizumab. In I-SPY2, IO-positive cancers (45.9%) had pCR rates of 85.7% and 16%, with and without immunotherapy, respectively. In IOnegative cancers, pCR rates were 46.7% versus 16.1%.\u003Cbr>Conclusions: DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1 . |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nImmunotherapies using immune checkpoint inhibitors (ICI) are now standard of care in the treatment of many solid tumors (1, 2) . Although ICIs can improve clinical outcomes, only a subset of  \n1Department of Medical Oncology,","cbCairmaEo3HNZEW","https://ap.wps.com/l/cbCairmaEo3HNZEW","pdf",2451305,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What does DetermaIO evaluate in triple-negative breast cancer?\",\"answer\":\"DetermaIO is a 27-gene RT-qPCR–based assay that generates an immune-related score. The study evaluates whether this score predicts sensitivity to immune checkpoint therapy.\"},{\"question\":\"How were DetermaIO results validated in this research?\",\"answer\":\"The study compared the DetermaIO score from RT-qPCR with an equivalent score calculated from RNA-seq data. It further assessed predictive performance across trials, including neoTRIPaPDL1 and I-SPY2.\"},{\"question\":\"Does PD-L1 expression predict benefit from atezolizumab in these analyses?\",\"answer\":\"No. The study reports that PDL1 protein expression was not predictive of differential benefit from atezolizumab.\"}]","The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer | PDF",1789999094,25]